BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e202175. [PMID: 32250434 DOI: 10.1001/jamanetworkopen.2020.2175] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Cao Y, Zheng Y, Dong Y, Ma J, Zhu W, Liu C. Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. Cardiovasc Drugs Ther 2021;35:273-81. [PMID: 33538928 DOI: 10.1007/s10557-021-07144-8] [Reference Citation Analysis]
2 Pun PH, Pokorney SD, Granger CB. Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease: If You Are Not Confused, You Are Not Thinking Clearly. JACC Clin Electrophysiol 2020;6:1669-71. [PMID: 33334445 DOI: 10.1016/j.jacep.2020.07.020] [Reference Citation Analysis]
3 See L, Lee H, Chao T, Li P, Liu J, Wu L, Chang S, Yeh Y, Kuo C, Chan Y, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc Drugs Ther 2021;35:975-86. [DOI: 10.1007/s10557-020-07108-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Vio R, Proietti R, Rigato M, Calò LA. Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. Pharmaceuticals (Basel) 2021;14:279. [PMID: 33808739 DOI: 10.3390/ph14030279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rossini R, Casula M, Ferlini M. Atrial fibrillation in advanced renal failure: are there alternative solutions to warfarin-dicumarol? Eur Heart J Suppl 2021;23:E138-41. [PMID: 34650373 DOI: 10.1093/eurheartj/suab109] [Reference Citation Analysis]
6 Lau WL. Controversies: Stroke Prevention in Chronic Kidney Disease. J Stroke Cerebrovasc Dis 2021;30:105679. [PMID: 33640261 DOI: 10.1016/j.jstrokecerebrovasdis.2021.105679] [Reference Citation Analysis]
7 Panahi L, Udeani G, Horseman M, Weston J, Samuel N, Joseph M, Mora A, Bazan D. Review of Medical Therapies for the Management of Pulmonary Embolism. Medicina (Kaunas) 2021;57:110. [PMID: 33530544 DOI: 10.3390/medicina57020110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021;32:1474-83. [PMID: 33753537 DOI: 10.1681/ASN.2020111566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
9 Starr JA, Pinner NA, Mannis M, Stuart MK. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Ann Pharmacother 2021;:10600280211040093. [PMID: 34459281 DOI: 10.1177/10600280211040093] [Reference Citation Analysis]
10 Xu R, Wu F, Lan J, Duan P. Real-world comparison of direct-acting oral anticoagulants and vitamin K antagonists in chronic kidney disease: a systematic review and meta-analysis. Expert Rev Hematol 2021;14:493-502. [PMID: 33949923 DOI: 10.1080/17474086.2021.1920012] [Reference Citation Analysis]
11 Levy DS, Grewal R, Le TH. Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease. Am J Physiol Renal Physiol 2020;319:F618-23. [PMID: 32830534 DOI: 10.1152/ajprenal.00278.2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
13 Wadsworth D, Sullivan E, Jacky T, Sprague T, Feinman H, Kim J. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther 2021;46:560-70. [PMID: 33393699 DOI: 10.1111/jcpt.13343] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lin CJ, Chien MH, Yang MJ, Lin MH, Hsu CC, Chu PL. Trends of medication used in patients with pre-ESKD from 2010 to 2018 in Taiwan. J Formos Med Assoc 2021:S0929-6646(21)00577-5. [PMID: 34980550 DOI: 10.1016/j.jfma.2021.12.012] [Reference Citation Analysis]
15 Belley-Cote EP, Eikelboom JW. Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Disease-First, Do No Harm. JAMA Netw Open 2020;3:e202237. [PMID: 32250429 DOI: 10.1001/jamanetworkopen.2020.2237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Kimura A, Tanaka M, Moniwa N, Osanami A, Abe K, Miyamori D, Gocho Y, Shibata S, Terasawa M, Okazaki Y, Yamashita T, Koyama M, Furuhashi M, Ohnishi H, Miura T. Impact of atrial fibrillation on the risk of ischemic stroke in patients on hemodialysis: BOREAS-HD3 Study. Clin Exp Nephrol 2021;25:297-304. [PMID: 33206249 DOI: 10.1007/s10157-020-01991-9] [Reference Citation Analysis]
17 Lamarche MC, Alrajhi E, Wells PS. Direct oral anticoagulant use in special populations. Curr Opin Pulm Med 2021;27:311-8. [PMID: 34115699 DOI: 10.1097/MCP.0000000000000787] [Reference Citation Analysis]
18 Dobesh PP, Kernan MM, Lueshen JJ. Direct Oral Anticoagulants in the Treatment of Venous Thromboembolism: Use in Patients with Advanced Renal Impairment, Obesity, or Other Weight-Related Special Populations. Semin Respir Crit Care Med 2021;42:233-49. [PMID: 33601428 DOI: 10.1055/s-0041-1723952] [Reference Citation Analysis]
19 Stefil M, Nabrdalik K, Lip GY. Renal Disease and Atrial Fibrillation. Cardiac Electrophysiology Clinics 2021;13:95-112. [DOI: 10.1016/j.ccep.2020.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lee KH, Ou SM, Chu YC, Lin YP, Tsai MT, Tarng DC. Antithrombotic Therapy for Chronic Kidney Disease Patients With Concomitant Atrial Fibrillation and Coronary Artery Disease. Front Cardiovasc Med 2021;8:751359. [PMID: 34692798 DOI: 10.3389/fcvm.2021.751359] [Reference Citation Analysis]
21 Andrade JG, Aguilar M, Atzema C, Bell A, Cairns JA, Cheung CC, Cox JL, Dorian P, Gladstone DJ, Healey JS, Khairy P, Leblanc K, McMurtry MS, Mitchell LB, Nair GM, Nattel S, Parkash R, Pilote L, Sandhu RK, Sarrazin JF, Sharma M, Skanes AC, Talajic M, Tsang TSM, Verma A, Verma S, Whitlock R, Wyse DG, Macle L; Members of the Secondary Panel. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol 2020;36:1847-948. [PMID: 33191198 DOI: 10.1016/j.cjca.2020.09.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 20.5] [Reference Citation Analysis]
22 Benito-gonzález T, Quirós A, Torres-saura F, Cruz-gonzález I, Ruiz-nodar JM, Pérez de Prado A. Diseño y resultados intermedios del registro de cierre de orejuela izquierda con el dispositivo Watchman en pacientes en hemodiálisis, EPIC06-WATCH-HD. Revista Española de Cardiología 2022;75:179-81. [DOI: 10.1016/j.recesp.2021.07.016] [Reference Citation Analysis]
23 Brieger D, Freedman B. Decoding stroke risk scores in atrial fibrillation: still more work to do. Eur Heart J 2021;42:1486-8. [PMID: 33824965 DOI: 10.1093/eurheartj/ehaa1111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 De Vriese AS, Heine G. Anticoagulation Management In Hemodialysis Patients With Atrial Fibrillation: Evidence And Opinion. Nephrol Dial Transplant 2021:gfab060. [PMID: 33647941 DOI: 10.1093/ndt/gfab060] [Reference Citation Analysis]
25 Chandrasegaram A, Peters CD. The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review. Semin Dial 2022. [PMID: 35623902 DOI: 10.1111/sdi.13098] [Reference Citation Analysis]
26 Law MM, Wong MC, Morton JB. Atrial Fibrillation: More Than a Subclinical Problem in Patients on Hemodialysis. Kidney International Reports 2022;7:141-3. [DOI: 10.1016/j.ekir.2021.11.023] [Reference Citation Analysis]